Patents by Inventor Keith H. Crawford
Keith H. Crawford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911398Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: GrantFiled: April 22, 2021Date of Patent: February 27, 2024Assignee: OPKO RENAL, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Patent number: 11452734Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: GrantFiled: April 24, 2020Date of Patent: September 27, 2022Assignee: EIRGEN PHARMA LTD.Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
-
Patent number: 11154509Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: October 5, 2017Date of Patent: October 26, 2021Assignees: EIRGEN PHARMA LTD., OPKO RENAL, LLCInventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
-
Publication number: 20210236517Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: ApplicationFiled: April 22, 2021Publication date: August 5, 2021Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Patent number: 11007204Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: GrantFiled: October 25, 2018Date of Patent: May 18, 2021Assignee: OPKO RENAL, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Publication number: 20200253987Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: ApplicationFiled: April 24, 2020Publication date: August 13, 2020Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
-
Patent number: 10668089Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: GrantFiled: March 12, 2018Date of Patent: June 2, 2020Assignees: OPKO IRELAND GLOBAL HOLDINGS, LTD., OPKO RENAL, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
-
Publication number: 20190060329Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: ApplicationFiled: October 25, 2018Publication date: February 28, 2019Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Patent number: 10213442Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: GrantFiled: October 2, 2017Date of Patent: February 26, 2019Assignee: OPKO RENAL, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Publication number: 20180296576Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: ApplicationFiled: March 12, 2018Publication date: October 18, 2018Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
-
Patent number: 9943530Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: GrantFiled: November 19, 2014Date of Patent: April 17, 2018Assignee: OPKO RENAL, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Patent number: 9925147Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: November 21, 2016Date of Patent: March 27, 2018Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LIMITEDInventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Eric J. Messner, P. Martin Petkovich, Keith H. Crawford
-
Patent number: 9918940Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: June 16, 2014Date of Patent: March 20, 2018Assignees: OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
-
Patent number: 9913852Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: GrantFiled: July 27, 2016Date of Patent: March 13, 2018Assignees: OPKO IRELAND GLOBAL HODLINGS, LTD., OPKO RENAL, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
-
Publication number: 20180028453Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: October 5, 2017Publication date: February 1, 2018Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
-
Publication number: 20180021356Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: ApplicationFiled: October 2, 2017Publication date: January 25, 2018Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Publication number: 20170119677Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: November 21, 2016Publication date: May 4, 2017Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Eric J. Messner, P. Martin Petkovich, Keith H. Crawford
-
Publication number: 20170027962Abstract: Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also disclosed.Type: ApplicationFiled: October 10, 2016Publication date: February 2, 2017Inventors: P. Martin Petkovich, Charles W. Bishop, Eric J. Messner, Keith H. Crawford
-
Publication number: 20160346299Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: August 8, 2016Publication date: December 1, 2016Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Eric J. Messner, P. Martin Petkovich, Keith H. Crawford
-
Patent number: 9498486Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: August 8, 2016Date of Patent: November 22, 2016Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Eric J. Messner, P. Martin Petkovich, Keith H. Crawford